Acumen Pharmaceuticals (ABOS) Cash & Equivalents (2020 - 2026)

Acumen Pharmaceuticals' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $51.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 71.74% year-over-year to $51.8 million; the TTM figure through Mar 2026 stood at $51.8 million (up 71.74% YoY), while the FY2025 annual figure was $54.0 million, up 52.94% from the prior year.
• Cash & Equivalents came in at $51.8 million for Q1 2026 at Acumen Pharmaceuticals, down from $54.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $157.5 million in Q3 2022 to a low of $30.2 million in Q1 2025.
• A 5-year average of $72.1 million and a median of $66.2 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 65.04% in 2024 and soared 71.74% in 2026, its largest moves.
• Acumen Pharmaceuticals' Cash & Equivalents stood at $129.1 million in 2022, then sank by 48.72% to $66.2 million in 2023, then tumbled by 46.68% to $35.3 million in 2024, then surged by 52.94% to $54.0 million in 2025, then dropped by 4.06% to $51.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $51.8 million, $54.0 million, and $46.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison